Loading...
Docoh

Genmab (GMAB)

Utility
Inert Format
21 Oct 20
Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain.
Aran Frank LABRIJN, Joyce I. MEESTERS, Joost J. NEIJSSEN, Edward Norbert VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
Filed: 5 Feb 20
Utility
Human Monoclonal Antibodies Against CD20
7 Oct 20
Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed.
Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G.J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
Filed: 19 Nov 19
Utility
Monoclonal antibodies against HER2 epitope
5 Oct 20
Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed.
Bart De Goeij, Edward N. Van Den Brink, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, David Satijn, Jan Van De Winkel, Paul Parren
Filed: 19 Jun 17
Utility
Antibodies Against CD38 for Treatment of Multiple Myeloma
9 Sep 20
Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed.
Michel DE WEERS, Yvo GRAUS, Judith OPRINS, Paul PARREN, Jan VAN DE WINKEL, Martine VAN VUGT
Filed: 17 Feb 20
Utility
Antibodies binding AXL
7 Sep 20
The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
Filed: 14 Jan 19
Utility
Antibodies
2 Sep 20
The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3.
David SATIJN, Esther C. W. BREIJ, Bart E. C. G. DE GOEIJ, Kristel KEMPER, Patrick ENGELBERTS, Edward N. VAN DEN BRINK, Rik RADEMAKER, Dennis VERZIJL, Sjeng HORBACH, Paul PARREN
Filed: 8 Mar 20
Utility
Bispecific Antibodies Against HER2 and CD3
26 Aug 20
Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed.
Joost J. NEIJSSEN, Joyce I. MEESTERS, Bart DE GOEIJ, Aran Frank LABRIJN, Paul PARREN, Janine SCHUURMAN
Filed: 28 Oct 19
Utility
Stable IgG4 antibodies
24 Aug 20
The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament.
Jan Van De Winkel, Tom Vink, Janine Schuurman, Paul Parren, Rob Aalberse, Marijn Van Der Neut Kolfschoten
Filed: 28 Jun 16
Utility
Heterodimeric Antibody Fc-containing Proteins and Methods for Production Thereof
19 Aug 20
Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins
Aran Frank LABRIJN, Joyce I. MEESTERS, Ewald T. J. VAN DEN BREMER, Joost J. NEIJSSEN, Patrick VAN BERKEL, Bart DE GOEIJ, Tom VINK, Jan VAN DE WINKEL, Janine SCHUURMAN, Paul PARREN
Filed: 29 Jan 20
Utility
Antibody-drug Conjugate Lyophilised Formulation
5 Aug 20
Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof.
Jesper VALBJØRN, Xiaona JING, Kelly Ann ROBY, Timothy Warren PAUL, Gregory Allan SACHA, Nathan Alan PEASE, Bodil WILLUMSEN
Filed: 13 Jan 20
Utility
Multispecific Antibodies Against CD40 and CD137
5 Aug 20
Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Friederike GIESEKE, Ugur SAHIN
Filed: 21 Apr 20
Utility
Antibodies Against PD-L1
29 Jul 20
The present invention relates to novel antibodies and their use in medicine.
Isil ALTINTAS, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rik RADEMAKER, Paul PARREN, Bart DE GOEIJ
Filed: 8 Mar 18
Utility
Human monoclonal antibodies against CD25
6 Jul 20
Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed.
Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
Filed: 30 Jan 17
Utility
Humanized or Chimeric CD3 Antibodies
24 Jun 20
The present invention relates to humanized or chimeric antibodies binding CD3.
Edward Norbert VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Isil ALTINTAS, Paul PARREN, Rik RADEMAKER
Filed: 18 Aug 19
Utility
Bispecific Antibodies Against CD3 and CD20
24 Jun 20
Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
Patrick ENGELBERTS, Esther BREIJ, Rik RADEMAKER, Isil ALTINTAS, David SATIJN, Sandra VERPLOEGEN, Riemke VAN DIJKHUIZEN RADERSMA, Edward VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
Filed: 3 Dec 19
Utility
Antibodies Binding Axl
3 Jun 20
The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
Filed: 3 Nov 19
Utility
Binding Agents Binding to PD-L1 and CD137 and Use Thereof
27 May 20
The present invention relates to novel binding agents and their use in medicine.
Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
Filed: 30 Jan 20
Utility
Variants of CD38 Antibody and Uses Thereof
27 May 20
Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.
Bart De GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David P.E. SATIJN, Tahamtan AHMADI
Filed: 9 Feb 20
Utility
Modulation of Complement-dependent Cytotoxicity Through Modifications of the C-terminus of Antibody Heavy Chains
29 Apr 20
Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described.
Paul PARREN, Patrick VAN BERKEL, Ewald VAN DEN BREMER
Filed: 29 Apr 19
Utility
Humanized or Chimeric CD3 Antibodies
22 Apr 20
The present invention relates to humanized or chimeric antibodies binding CD3.
Edward VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Paul PARREN
Filed: 24 Sep 19
Patents are sorted by USPTO publication date, most recent first